FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden

hours per response:

0.5

	Check this box if no longer subject to							
)	Section 16. Form 4 or Form 5							
J	obligations may continue. See							
	Instruction 1(b).							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						,										
Name and Address of Reporting Person* Purlog John D.					2. Issuer Name and Ticker or Trading Symbol Akebia Therapeutics, Inc. [AKBA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Butler John P.				incom incrupeutics, inc. [mcon]							X Director		10% Ov	vner		
													(give title	Other (s	pecify	
(Last)	(F	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)							below) below)				
C/O AKEBIA THERAPEUTICS, INC.					03/06/2015						CEO and President					
245 FIRS	ST STREET	Γ, SUITE 1100														
				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable				
(Street)											Line	,				
CAMBR	IDGE M	ſΑ	02142									_	,	eporting Persor		
												Form fil Person	ed by More th	han One Repor	ting	
(City)	(S	State)	(Zip)									1 013011				
		Та	ble I - Non-D	erivati	ve Se	ecurities	s Ac	quired, D	isposed (of, or Be	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transaction 3.										7. Nature of						
				te onth/Day/Year)		Execution Date, if any		Code (Ins				Beneficia	lly (D) o) or Indirect	ndirect Beneficial	
						(Month/Day/Yea		ar) 8)				Owned Fe			Ownership (Instr. 4)	
								Code V Amount		(A) o (D)	r Price	Transaction(s) (Instr. 3 and 4)				
			Table II - De	rivativ	9 500	uritias	Δςα	uired Dis	nosed of	or Ren	eficially	Owned				
								s, options	•	•	•	Owned				
1. Title of 2. 3. Transaction 3A. Deemed 4.					5. Number of 6. Date Exercisable and 7. Title and Amo		d Amount	8. Price of	9. Number o	f 10.	11. Nature					
		Execution Date, if any					Expiration Date of Securities (Month/Day/Year) Underlying			Derivative Security	derivative Securities	Ownership Form:	of Indirect Beneficial			
			(Month/Day/Yea		8) Acquired (A) or Disposed of (D) (Instr.		Acquired (A)		Derivative Secui (Instr. 3 and 4)		Security	(Instr. 5)	Beneficially Owned		Ownership (Instr. 4)	
Security				(instr. 3 and 4)			iu 4)		Following	(i) (instr. 4)	(111501. 4)					
						3, 4 and 5)							Reported Transaction(s)	(s)		
											Amount or		(Instr. 4)	``		
				Code	l _v	(0)		Date	Expiration	Tialo	Number					
_				Code	V	(A)	(D)	Exercisable	Date	Title	of Shares			_	-	
Stock Option		03/06/045		1.		450.000		(1)	02/06/205=	Common	150,000		450.000			
(Right to	\$11.15	03/06/2015		A		150,000		(1)	03/06/2025	Stock	150,000	\$0.00	150,000	D		
Buy)																

Explanation of Responses:

1. 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

Remarks:

Nicole R. Hadas, attorney-infact for John P. Butler

03/10/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.